PL2668209T3 - Przeciwciało selektywne dla komórek z wysoką gęstością egfr - Google Patents

Przeciwciało selektywne dla komórek z wysoką gęstością egfr

Info

Publication number
PL2668209T3
PL2668209T3 PL12738907T PL12738907T PL2668209T3 PL 2668209 T3 PL2668209 T3 PL 2668209T3 PL 12738907 T PL12738907 T PL 12738907T PL 12738907 T PL12738907 T PL 12738907T PL 2668209 T3 PL2668209 T3 PL 2668209T3
Authority
PL
Poland
Prior art keywords
high density
cells presenting
antibodies selective
egfr
presenting egfr
Prior art date
Application number
PL12738907T
Other languages
English (en)
Inventor
Ilia Alexandre Tikhomirov
Maria L. Jaramillo
Maureen D. O'connor-Mccourt
Traian Sulea
Renald Gilbert
Bruno Gaillet
Jason Baardsnes
Myriam Banville
Suzanne GROTHE
Original Assignee
Gilead Sciences, Inc.
National Research Council Of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc., National Research Council Of Canada filed Critical Gilead Sciences, Inc.
Publication of PL2668209T3 publication Critical patent/PL2668209T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL12738907T 2011-01-24 2012-01-20 Przeciwciało selektywne dla komórek z wysoką gęstością egfr PL2668209T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161435510P 2011-01-24 2011-01-24
EP12738907.0A EP2668209B8 (en) 2011-01-24 2012-01-20 Antibodies selective for cells presenting egfr at high density
PCT/CA2012/050034 WO2012100346A1 (en) 2011-01-24 2012-01-20 Antibodies selective for cells presenting egfr at high density

Publications (1)

Publication Number Publication Date
PL2668209T3 true PL2668209T3 (pl) 2021-11-02

Family

ID=46580157

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12738907T PL2668209T3 (pl) 2011-01-24 2012-01-20 Przeciwciało selektywne dla komórek z wysoką gęstością egfr

Country Status (10)

Country Link
US (2) US10570211B2 (pl)
EP (1) EP2668209B8 (pl)
AU (1) AU2012211014A1 (pl)
CA (2) CA3115406A1 (pl)
ES (1) ES2860748T3 (pl)
PL (1) PL2668209T3 (pl)
PT (1) PT2668209T (pl)
RU (1) RU2013138177A (pl)
SI (1) SI2668209T1 (pl)
WO (1) WO2012100346A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570211B2 (en) 2011-01-24 2020-02-25 Gilead Sciences, Inc. Antibodies selective for cells presenting EGFR at high density
US20150322152A1 (en) * 2012-11-30 2015-11-12 Institut Pasteur Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
US20170319709A1 (en) 2013-07-05 2017-11-09 Formation Biologics Inc. Egfr antibody conjugates
KR20160145802A (ko) 2014-04-23 2016-12-20 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법
WO2016065456A1 (en) * 2014-10-31 2016-05-06 Formation Biologics Inc. Egfr antibody-based combination therapy
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
US12392777B2 (en) 2019-04-02 2025-08-19 National Research Council Of Canada Antibody variants with pH-dependent antigen binding for selective targeting of solid tumors
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
PH12022552076A1 (en) 2020-02-12 2023-11-29 Janssen Biotech Inc TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS
EP4247853A4 (en) 2020-11-20 2025-02-12 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. MODIFIED EGFR ANTIBODY WITH REDUCED AFFINITY, DRUG CONJUGATE AND USE THEREOF
US20240239905A1 (en) * 2021-05-13 2024-07-18 Arizona Board Of Regents On Behalf Of Arizona State University A plant produced anti-egfr mabs with specific glycosylation to improve the efficacy against cancer
WO2023244276A2 (en) * 2021-10-13 2023-12-21 The Wistar Institute Of Anatomy And Biology DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1191944A2 (en) 1999-06-25 2002-04-03 Genentech, Inc. METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
ES2533963T3 (es) 2002-10-10 2015-04-16 Merck Patent Gmbh Composiciones farmacéuticas dirigidas a receptores Erb-B1
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CN102558352A (zh) 2003-06-27 2012-07-11 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
WO2006009694A2 (en) 2004-06-14 2006-01-26 Imclone Sysetms Incorporated Crystal of egfr extracellular domain and cetuximab fab fragment and uses thereof
CN101675075B (zh) * 2007-03-01 2014-06-18 西福根有限公司 重组抗表皮生长因子受体抗体组合物
CN103298489A (zh) 2010-10-29 2013-09-11 伊缪诺金公司 新型egfr结合分子及其免疫偶联物
WO2012075581A1 (en) 2010-12-06 2012-06-14 Ym Biosciences Inc. Antibodies selective for cells presenting erbb2 at high density
US10570211B2 (en) 2011-01-24 2020-02-25 Gilead Sciences, Inc. Antibodies selective for cells presenting EGFR at high density
US9233171B2 (en) 2011-11-21 2016-01-12 Immunogen, Inc. Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate
KR20220041957A (ko) 2013-03-15 2022-04-01 아비에 도이치란트 게엠베하 운트 콤파니 카게 항-egfr 항체 약물 접합체 제형
US20170319709A1 (en) 2013-07-05 2017-11-09 Formation Biologics Inc. Egfr antibody conjugates

Also Published As

Publication number Publication date
EP2668209A1 (en) 2013-12-04
WO2012100346A1 (en) 2012-08-02
EP2668209A4 (en) 2015-08-05
CA3115406A1 (en) 2012-08-02
US10570211B2 (en) 2020-02-25
US20200325243A1 (en) 2020-10-15
ES2860748T3 (es) 2021-10-05
EP2668209B1 (en) 2020-12-30
US12084510B2 (en) 2024-09-10
SI2668209T1 (sl) 2021-05-31
AU2012211014A1 (en) 2013-05-02
CA2825255C (en) 2021-05-18
PT2668209T (pt) 2021-04-07
EP2668209B8 (en) 2021-08-11
CA2825255A1 (en) 2012-08-02
US20130295086A1 (en) 2013-11-07
RU2013138177A (ru) 2015-03-10

Similar Documents

Publication Publication Date Title
PT2668209T (pt) Anticorpos seletivos para células que apresentam egfr em alta densidade
GB2491209B (en) Solar cell and method for producing same
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
ZA201305323B (en) Cea antibodies
GB201115529D0 (en) Antibodies, uses and methods
GB201115280D0 (en) Antibodies, uses and methods
GB201103590D0 (en) Fuel cell
EP2775557A4 (en) FUEL CELL
SI2780717T1 (sl) Adrenomedulinski testi in postopki za določevanje zrelega adrenomedulina
PT2542576T (pt) Métodos para rastreio de anticorpos
ZA201305116B (en) Fuel cells
ZA201400772B (en) Method for using vinasse
PH12012501884A1 (en) Humanized il-25 antibodies
EP2690694A4 (en) FUEL CELL
ZA201405069B (en) Fuel cell
EP2693546A4 (en) FUEL CELL
SG10201605531PA (en) Reconstitution methods
EP2706688A4 (en) SEARCH PROCESS FOR AN ADVANCED PDCCH AREA
EP2696414A4 (en) FUEL CELL
EP2693545A4 (en) FUEL CELL
PL2776552T3 (pl) Urządzenie do hodowli komórek
PL2729428T3 (pl) Sposób wypalania materiałów w formie bryłek
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
GB2498249B (en) Sealing method for battery holder.